Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
暂无分享,去创建一个
Marco Rovaris | Massimo Filippi | Frederik Barkhof | Gilles Edan | Per Soelberg Sørensen | Vittorio Martinelli | Hans-Peter Hartung | Giancarlo Comi | F. Barkhof | M. Rovaris | M. Filippi | H. Hartung | V. Martinelli | G. Comi | P. Sørensen | G. Edan | O. Hommes | L. Durelli | Luca Durelli | P. Seeldrayers | Oscar Fernández | Pierrette Seeldrayers | Otto R Hommes | Ó. Fernández
[1] G. Aimard,et al. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. , 1980, Brain : a journal of neurology.
[2] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[3] Neil R. Miller,et al. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .
[4] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[5] O. Stuve,et al. Interferon beta in the treatment of multiple sclerosis , 1998, Neurology.
[6] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[7] B D Trapp,et al. Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.
[8] G. Comi. Why treat early multiple sclerosis patients? , 2000, Current opinion in neurology.
[9] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[10] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[11] V. Perry,et al. Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.
[12] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[13] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[14] P M Matthews,et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.
[15] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[16] G. Comi,et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. , 2000, AJNR. American journal of neuroradiology.
[17] G. Comi,et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.
[18] R. Knobler,et al. A neurologic rating scale (NRS) for use in multiple sclerosis , 1984, Neurology.
[19] Ludwig Kappos,et al. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.
[20] D. Li,et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS , 2001, Neurology.
[21] G J Barker,et al. Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? , 1999, Journal of neurology, neurosurgery, and psychiatry.
[22] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[23] P. Calabresi,et al. Interferon beta results in immediate reduction of contrast‐enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI , 1997, Neurology.
[24] Nick C Fox,et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS , 2000, Neurology.
[25] G. Comi,et al. Paraclinical tests in acute‐onset optic neuritis: basal data and results of a short follow‐up , 1991, Acta neurologica Scandinavica.
[26] A. Thompson,et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[27] A. Thompson,et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.
[28] M Rovaris,et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis , 1997, Neurology.
[29] W. I. McDonald,et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.